ProThera Biologics Inc. Secures $500,000 New Funding
ProThera Biologics Inc.
551 Warren Avenue East Providence, RI 02914
The mission of the company is to develop novel products that exploit the promise of personalized medicine by leveraging on its proprietary technology of natural serine protease inhibitor proteins.
The company focuses on unmet medical needs by developing INTEGRATED theranostic and therapeutic biomolecules for serious human diseases such as sepsis and cancer.
Richard Horan of the Slater Technology Fund said, “With additional investment and with Rick Andrews coming on-board, we are excited about the prospects of accelerating the company’s efforts in the development of what promise to be significant advances in clinical medicine.”
Slater Technology Fund
Trending on Xconomy
[toplytics period="week" numberposts="3"]